- Home
- NMCO vs PLRX Comparison
NMCO vs PLRX Comparison
Compare NMCO & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMCO
- PLRX
- Stock Information
- Founded
- NMCO 2019
- PLRX 2015
- Country
- NMCO United States
- PLRX United States
- Employees
- NMCO N/A
- PLRX N/A
- Industry
- NMCO Finance/Investors Services
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- NMCO Finance
- PLRX Health Care
- Exchange
- NMCO Nasdaq
- PLRX Nasdaq
- Market Cap
- NMCO 611.9M
- PLRX 641.5M
- IPO Year
- NMCO N/A
- PLRX 2020
- Fundamental
- Price
- NMCO $10.48
- PLRX $13.21
- Analyst Decision
- NMCO
- PLRX Strong Buy
- Analyst Count
- NMCO 0
- PLRX 7
- Target Price
- NMCO N/A
- PLRX $40.50
- AVG Volume (30 Days)
- NMCO 207.6K
- PLRX 591.6K
- Earning Date
- NMCO 01-01-0001
- PLRX 11-07-2024
- Dividend Yield
- NMCO 5.43%
- PLRX N/A
- EPS Growth
- NMCO N/A
- PLRX N/A
- EPS
- NMCO N/A
- PLRX N/A
- Revenue
- NMCO N/A
- PLRX N/A
- Revenue This Year
- NMCO N/A
- PLRX N/A
- Revenue Next Year
- NMCO N/A
- PLRX N/A
- P/E Ratio
- NMCO N/A
- PLRX N/A
- Revenue Growth
- NMCO N/A
- PLRX N/A
- 52 Week Low
- NMCO $8.52
- PLRX $10.22
- 52 Week High
- NMCO $11.64
- PLRX $19.62
- Technical
- Relative Strength Index (RSI)
- NMCO 23.25
- PLRX 43.89
- Support Level
- NMCO $10.40
- PLRX $13.14
- Resistance Level
- NMCO $11.25
- PLRX $15.00
- Average True Range (ATR)
- NMCO 0.14
- PLRX 0.81
- MACD
- NMCO -0.07
- PLRX -0.12
- Stochastic Oscillator
- NMCO 7.65
- PLRX 5.13
About NMCO Nuveen Municipal Credit Opportunities Fund
Nuveen Municipal Credit Opps Fund is a closed-end fund. The fund's objective is to provide a high level of current income exempt from regular U.S. federal income tax and secondarily, total return. It invests in high yielding, low-to medium-quality municipal securities and uses leverage.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.